Quest for the right Drug
מולקולות חדשות
אספבלי ASPAVELI
תאריך רישום: June 5, 2023
מסלול הגשה: מולקולה חדשה
יצרן: CANGENE BIOPHARMA LLC., USA
בעל רישום: TRUEMED LTD, ISRAEL
L04AA54 :ATC Code
4.1 Therapeutic indications ASPAVELI is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.
לדף התרופה >אלפבריו ELFABRIO
תאריך רישום: June 26, 2023
מסלול הגשה: מולקולה חדשה
יצרן: CHIESI FARMACEUTICI S.P.A., ITALY
בעל רישום: MEGAPHARM LTD
A16AB20 :ATC Code
דואק DUAC
תאריך רישום: July 14, 2013
מסלול הגשה: מולקולה חדשה
יצרן: GLAXO OPERATIONS UK LIMITED (TRADING AS GLAXO WELLCOME OPERATIONS)
בעל רישום: PADAGIS ISRAEL AGENCIES LTD, ISRAEL
D10AF01 :ATC Code
4.1 Therapeutic indications Mild to moderate acne vulgaris, particularly inflammatory lesions.
לדף התרופה >אולטרביסט 300 ULTRAVIST 300
תאריך רישום: May 26, 1994
מסלול הגשה: מולקולה חדשה
יצרן: BAYER AG, GERMANY
בעל רישום: BAYER ISRAEL LTD
V08AB05 :ATC Code
4.1 Therapeutic indications This medicinal product is for diagnostic use only. Ultravist 300: Contrast enhancement in computerized tomography (CT), digital subtraction angiography (DSA), intravenous urography, arteriography, phlebography of the extremities, venography, visualization of body cavities (e.g. arthrography, hysterosalpingography, fistulography) with the exception of myelography, ventriculography, cisternography. Ultravist 370: Contrast enhancement in computerized tomography (CT), digital subtraction angiography (DSA), intravenous urography, arteriography and especially angiocardiography, visualization of body cavities (e.g. arthrography, fistulography) with the exception of myelography, ventriculography, cisternography.
לדף התרופה >טיקוואק 0.5 מ"ל TICOVAC 0.5 ML
תאריך רישום: November 5, 2017
מסלול הגשה: מולקולה חדשה
יצרן: PFIZER MANUFACTURING AUSTRIA GMBH, AUSTRIA
בעל רישום: PFIZER PHARMACEUTICALS ISRAEL LTD
J07BA01 :ATC Code
4.1 Therapeutic indications TicoVac 0.5 ml is indicated for the active (prophylactic) immunization of adolescents from 16 years of age and adults against tick-borne encephalitis (TBE). TicoVac 0.5 ml is to be given on the basis of official recommendations regarding the need for, and timing of, vaccination against TBE.
לדף התרופה >טיקוואק ג'וניור 0.25 מ"ל TICOVAC JUNIOR 0.25 ML
תאריך רישום: November 5, 2017
מסלול הגשה: מולקולה חדשה
יצרן: PFIZER MANUFACTURING AUSTRIA GMBH, AUSTRIA
בעל רישום: PFIZER PHARMACEUTICALS ISRAEL LTD
J07BA01 :ATC Code
4.1 Therapeutic indications TicoVac Junior 0.25 ml is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (TBE). TicoVac Junior 0.25 ml is to be given on the basis of official recommendations regarding the need for, and timing of, vaccination against TBE.
לדף התרופה >
